[go: up one dir, main page]

CL2007003444A1 - Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. - Google Patents

Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.

Info

Publication number
CL2007003444A1
CL2007003444A1 CL200703444A CL2007003444A CL2007003444A1 CL 2007003444 A1 CL2007003444 A1 CL 2007003444A1 CL 200703444 A CL200703444 A CL 200703444A CL 2007003444 A CL2007003444 A CL 2007003444A CL 2007003444 A1 CL2007003444 A1 CL 2007003444A1
Authority
CL
Chile
Prior art keywords
pirrolo
piridine
treatment
pharmaceutical composition
inflammatory disease
Prior art date
Application number
CL200703444A
Other languages
English (en)
Inventor
Karen Price Stephen D Williams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2007003444A1 publication Critical patent/CL2007003444A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200703444A 2006-11-30 2007-11-29 Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. CL2007003444A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
CL2007003444A1 true CL2007003444A1 (es) 2008-06-27

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703444A CL2007003444A1 (es) 2006-11-30 2007-11-29 Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.

Country Status (15)

Country Link
US (1) US7855216B2 (es)
EP (1) EP2099796B1 (es)
JP (1) JP5211063B2 (es)
AR (1) AR064031A1 (es)
AT (1) ATE511509T1 (es)
AU (1) AU2007325123B2 (es)
CA (1) CA2672327A1 (es)
CL (1) CL2007003444A1 (es)
DK (1) DK2099796T3 (es)
HK (1) HK1135099A1 (es)
PE (1) PE20081354A1 (es)
PL (1) PL2099796T3 (es)
PT (1) PT2099796E (es)
TW (1) TW200829586A (es)
WO (1) WO2008067481A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2729635A1 (en) * 2008-07-03 2010-01-07 Ananth Srinivasan Compounds and processes for production of radiopharmaceuticals
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Mek阻害剤に対する耐性を付与するmek突然変異
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CA2791247C (en) 2010-03-09 2019-05-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2806332C (en) * 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
AU2018270292B2 (en) 2017-05-19 2022-02-10 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
WO2018213810A1 (en) * 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
US20250101019A1 (en) * 2022-01-28 2025-03-27 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2023166450A1 (ko) * 2022-03-04 2023-09-07 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60313769T2 (de) 2002-04-23 2008-03-06 Aventis Pharmaceuticals Inc. 3-(pyridinyl-amino)-1h-indol-2-carbonsäure-verbindungen als inhibitoren der interleukin-4 genexpression
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
DK2099796T3 (da) 2011-09-05
AU2007325123A1 (en) 2008-06-05
ATE511509T1 (de) 2011-06-15
US20080242655A1 (en) 2008-10-02
TW200829586A (en) 2008-07-16
PT2099796E (pt) 2011-09-06
EP2099796A1 (en) 2009-09-16
WO2008067481A1 (en) 2008-06-05
PL2099796T3 (pl) 2011-10-31
CA2672327A1 (en) 2008-06-05
JP5211063B2 (ja) 2013-06-12
HK1135099A1 (en) 2010-05-28
AR064031A1 (es) 2009-03-04
JP2010511626A (ja) 2010-04-15
PE20081354A1 (es) 2008-11-14
US7855216B2 (en) 2010-12-21
AU2007325123B2 (en) 2012-12-13
EP2099796B1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SOLUBLE DEATH MEDICINE
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
EP1987825A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
IS8559A (is) Lyfjasamsetning gegn sveppagerlum
PL1890695T3 (pl) Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach